New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

New data from the PROSPER study highlight the significant benefits of mogamulizumab for patients with mycosis fungoides and Sézary syndrome, showing marked improvements in skin symptoms starting at just four weeks and continuing throughout the 48-week study. Presented at the 6th World Congress of Cutaneous Lymphomas, these findings underscore the potential of mogamulizumab to enhance the quality of life for those battling these rare skin lymphomas. This advancement is crucial as it provides a more effective treatment option, potentially transforming patient care and outcomes in the field of cutaneous lymphoma.